↧
More Patients with Type 2 Diabetes Reach HbA[1c] Target with Apidra® on top...
Paris (ots/PRNewswire) – - First Randomized Controlled Trial to Show That Basal Plus Regimen Provides more Effective Glycemic Control with Less Hypoglycemia Than with Aspart Premixed Insulin Sanofi...
View ArticleLyxumia® is First Diabetes Therapy of its Class Approved in Japan for use in...
Paris (ots/PRNewswire) – - First once-daily prandial GLP-1 receptor agonist offering a new treatment option for Japanese people living with type 2 diabetes – Sanofi announced today that Japan’s...
View Article